Aspire biopharma holdings, inc., announces public listing on nasdaq

The closing of the business combination with powerup acquisition corp. creates nasdaq-listed biopharmaceutical company dedicated to developing breakthrough innovations in fda approved drugs, nutraceuticals, and supplements aspire has multiple product candidates in key areas of medical needs such as a fast-acting aspirin product for cardiology emergencies and pain management, a proprietary viagra/cialis combination product, various bi-hormonal drugs such as testosterone, estrogen, weight loss, anti-seizure, and thyroid drugs. supplements such as pre-workout and melatonin are already being developed using aspire's proprietary sublingual delivery system.
NDAQ Ratings Summary
NDAQ Quant Ranking